Stockscreener 앱 받기
14.39
6.43%
0.87
시간 외 거래:
14.39
전일 마감가:
$13.52
열려 있는:
$14
하루 거래량:
379.11K
Relative Volume:
1.64
시가총액:
$1.84B
수익:
$7.50M
순이익/손실:
$-81.89M
주가수익비율:
0.2714
EPS:
53.0176
순현금흐름:
$-63.58M
1주 성능:
+4.05%
1개월 성능:
-7.70%
6개월 성능:
-2.90%
1년 성능:
+124.49%
1일 변동 폭
$13.99
$14.49
1주일 범위
$12.66
$14.49
52주 변동 폭
$6.00
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
14.39 | 1.73B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 개시 | William Blair | Outperform |
| 2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-06 | 개시 | Piper Sandler | Overweight |
| 2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2020-05-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-31 | 재개 | H.C. Wainwright | Buy |
| 2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-08-31 | 개시 | Oppenheimer | Outperform |
| 2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - ADVFN Brasil
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - GlobeNewswire Inc.
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Company’s Banking Stock: Dissecting a -4.28% Quarterly Revenue Decline Amid Growth - investchronicle.com
Novagold Resources Inc (NG) Stock: A Year of Decreases and Increases - investchronicle.com
TV’s 2025 Market Dance: Down -20.11% – Time to Invest? - investchronicle.com
Mesoblast Ltd ADR Inc. (MESO) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Cango Inc ADR (CANG) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Innodata Inc (INOD) Stock: A Year of Market Movement, Down and Up - investchronicle.com
BILL Holdings Inc Inc. (BILL) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Burford Capital Limited: Navigating Market Fluctuations with a 3.10B Market Cap - investchronicle.com
Chagee Holdings Ltd. ADR (CHA) Stock: A Year of Highs and Lows - investchronicle.com
Nano X Imaging Ltd (NNOX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
WGRX Stock Update: Wellgistics Health Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
ZTO’s Stock Market Adventure: -5.37% YTD Growth Amidst Volatility - investchronicle.com
MGRX’s Market Whiplash: -74.88% YTD Decline, -16.49% Plunge in 30 Days - investchronicle.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com India
Sonim Technologies Inc (SONM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
An In-Depth Look at Trident Digital Tech Holdings Ltd. ADR Inc. (TDTH) Price Performance During Market Crashes - investchronicle.com
BTCM: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
DallasNews Corporation (DALN) Stock: Uncovering 52-Week Market Trends - investchronicle.com
DraftKings Inc (DKNG) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
TSM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Krispy Kreme Inc (DNUT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil® - thecapitalclub.com.au
UPDATED: Your guide to February Reporting Season 2020 - Morningstar.com.au
21 Best-Performing Small-Cap Stocks for March 2025 - NerdWallet
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Mesoblast shares downgraded to hold by Jefferies By Investing.com - Investing.com South Africa
Why the Mesoblast share price is diving 18% after an FDA win - The Motley Fool Australia
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart.com
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):